Gujarat Themis Biosyn reports 36% rise in Q2 net profit

07 Nov 2022 Evaluate

Gujarat Themis Biosyn reported results for second quarter ended September 30, 2022.

The company has reported rise of 35.61% in its net profit at Rs 18.70 crore for Q2FY23 as compared to Rs 13.79 crore for the corresponding quarter previous year. Total income of the company increased by 37.28% to Rs 49.09 crore for the quarter under review as compared to Rs 35.76 crore for the same quarter in the previous year.

Gujarat Themis Biosyn Incorporated in 1981 as a joint sector company with GIIC and Chemosyn Commenced production in August, 1985 by producing Erythromycin and Erythromycin salts and formulations. The Company was taken over during June 1991 by Pharmaceutical Business Group.

Guj. Themis Biosyn Share Price

272.65 -12.50 (-4.38%)
30-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1830.20
Dr. Reddys Lab 1183.00
Cipla 1549.65
Lupin 2094.65
Zydus Lifesciences 887.70
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...